Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. Hardavella (London, United Kingdom). Photodynamic therapy (PDT) for the prevention of lung cancer (The Pearl Trial).. 4281

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of photodynamic therapy (PDT) in lung cancer treatment Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Photodynamic therapy (PDT) for in-situ (CIS) and micro-invasive (MCI) lungs cancer Source: Eur Respir J 2004; 24: Suppl. 48, 492s Year: 2004 Photodynamic therapy (PDT) in lung cancer with disease limited to endobronchial lesions Source: Eur Respir J 2004; 24: Suppl. 48, 699s Year: 2004 Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers Source: Eur Respir J 2006; 28: 200-218 Year: 2006 Photodynamic therapy using methylene blue in lung cancer animal models Source: Annual Congress 2013 –Therapeutical bronchoscopy for treatment of airway disorders: laser, stents and more Year: 2013 Regional laser centre experience in bronchoscopic photodynamic therapy (PDT) in inoperable bronchopulmonary cancer Source: Eur Respir J 2002; 20: Suppl. 38, 595s Year: 2002 Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC). Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer? Source: Eur Respir J 2003; 22: 535-541 Year: 2003 Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy) Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course Year: 2011 Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Efficiency of erythropoiesis-stimulating agents (ESA) in the treatment of chemotherapy-induced anemia in patients with lung cancer (LC) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Docetaxel (DOC) and gemcitabine (GEM) consist a safe and effective combination in the management of non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Interleukin 27 (IL27) as a novel therapeutic tool in lung cancer immune therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010